Email this article Diagnosis of moderate and high hypertriglyceridemia in patients in polyclinic practice: primary and secondary lipid metabolic disturbances
- Authors: Rozhkova T.A.1, Titov V.N.1, Amelyushkina V.A.1, Yarovaya E.B.1, Malyshev P.P.1, Meshkov A.N.1, Kukharchuk V.V.1, Rozhkova TA2, Titov VN2, Amelyushkina VA2, Yarovaya EB2, Malyshev PP2, Meshkov AN2, Kukharchuk VV2
-
Affiliations:
- A. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
- Issue: Vol 82, No 4 (2010)
- Pages: 10-17
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30557
- ID: 30557
Cite item
Full Text
Abstract
Subjects and methods. Patients (96 (54%) females) aged 12 to 71 years (median 50 years; quartiles, 41-61 years) with a TG level of more than 2.3 mmol/l and the following diseases: coronary heart disease (CHD) (44.8%), myocardial infarction (13.5%), arterial hypertension (87.9%), xanthomas (36.5%), and a family history of diseases (51%). The diagnosis of hyperlipidemia included a classical algorithm for clinical, biochemical, and clinicogenealogical examinations. Extended biochemical blood analysis, the determination of lipoprotein cholesterol (C), TG, low-density lipoprotein C, lipid electrophoresis, and assay of apolipoproteins A1, B-100, E, and C3 were made.
Results. The groups with moderate (m4.5 mmol/l and high (more than 4.5 mmol/l) blood triglycerides showed no differences in age and gender, systolic and diastolic blood pressures, the incidence of coronary heart disease, arterial hypertension, peripheral artery atherosclerosis, cardiac arrhythmias, and xanthomas. There was a significant correlation of high TG levels with smoking (a risk factor) and with the indicators of other metabolic disturbances - total C, chylomicrones, lipoprotein(a), LP-E-total, LP B:E, LP-C3-total, and LP-C3, which determined the impact of nutrition (and the development of pancreatitis), but also had a hereditary predisposition through the polygenic mechanisms of gene expression under the influence of a number of factors.
Conclusion. Higher TG levels correlated with the parameters, the diagnosis of which makes it possible to reveal additional metabolic disturbances via environmental and polygenic mechanisms.
About the authors
Tat'yana Alekseevna Rozhkova
Email: rozhkova.ta@mail.ru
Vladimir Nikolaevich Titov
Vera Alekseevna Amelyushkina
Email: Vera Aleks@mail.ru
Elena Borisovna Yarovaya
Pavel Prokop'evich Malyshev
Aleksey Nikolaevich Meshkov
Email: meshkov@cardio.ru
Valeriy Vladimirovich Kukharchuk
T A Rozhkova
A. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesA. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
V N Titov
A. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesA. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
V A Amelyushkina
A. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesA. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
E B Yarovaya
A. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesA. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
P P Malyshev
A. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesA. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
A N Meshkov
A. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesA. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
V V Kukharchuk
A. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical TechnologiesA. L. Myasnikov Cardiology Research Institute, Russian Cardiology Research-and-Production Complex, Russian Agency for Medical Technologies
References
- Климов Н. А., Никульчева Н. Г. Обмен липидов и липопротеидов и его нарушения: Руководство для врачей. СПб.: Питер-Ком, 1999.
- Fredrickson D. S., Lees R. S. System for fenotyping of hyperlipoproteinemia. Circulation 1965; 31: 321-327.
- Berg K. Genetic risk factors for atherosclerosis disease. In: Vogel F., Sperling K., eds. Human genetics. Berlin: Springer-Verlag; 1987. 326-335.
- Томпсон Г. Р. Руководство по гиперлипидемии. Репринт. Лондон; 1991.
- Титов В. Н., Амелюшкина В. А., Рожкова Т. А., Коткина Т. И. Диагностическое значение электрофореза липопротеинов при соматических заболеваниях - вторичных гиперлипопротеинемиях (лекция 2). Клин. лаб. диагн. 2008; 4: 21-36.
- Галлер Г., Ганефельд М., Яросс В. Нарушения липидного обмена. Диагностика. Клиника. Терапия: Пер. с нем. М.: Медицина; 1979.
- Титов В. Н. Клиническая биохимия жирных кислот, липидов и липопротеинов. Тверь: Триада; 2008.
- Титов В. Н. Лабораторная диагностика и диетотерапия гиперлипидемий (биологические основы). М.; 2006.
- Алмазов В. А., Благосклонная Я. В., Шляхто Е. В., Красильникова Е. И. Метаболический сердечно-сосудистый синдром. СПб.; 1999.
- Титов В. Н., Амелюшкина В. А., Рожкова Т. А. и др. Диагностика и дифференцированная, этиологически обоснованная диетотерапия при семейных формах гиперлипопротеинемии (лекция 1). Клин. лаб. диагн. 2008; 1: 23-34.
- Чазов Е. И. Проблемы первичной и вторичной профилактики сердечно-сосудистых заболеваний. Тер. арх. 2002; 9: 5-8.
- Austin M. A. Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond. Am. J. Epidemiol. 1989; 129: 249-259.
- Hulley S. B., Rosenman R. H., Bawol R. D. et al. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N. Engl. J. Med. 1980; 302: 1383-1389.
- Оганов Р. Г., Аронов Д. М., Бубнова М. Г. Применение статинов - парадигма профилактики и лечения атеросклеротических заболеваний (фокус на аторвастатин). Кардиоваск. тер. и профилакт. 2006; 5 (6): 95-106.
- Медикаментозная терапия метаболического синдрома: минимизация развивающегося кризиса полипрагмазии. Обзоры клинической кардиологии. Международ. мед. бюл. 2007: 11: 2-25.
- Лефебр Ф., Чинетти Дж., Фрушар Ж.-Ш., Стаелс Б. Распределение ролей рецептора PPARa в энергетическом метаболизме и сосудистом гомеостазе. ММБ. Обзоры клин. кардиол. 2009; 18: 2-18.
- Титов В. Н., Амелюшкина В. А., Рожкова Т. А. и др. Физико-химические методы диагностики гиперлипопротеинемий с определением концентрации аполипопротеинов и белков-векторов: Лекция 3. Клин. лаб. диагн. 2008; 5: 21- 36.
- Титов В. Н. Первичный и вторичный атеросклероз. Атероматоз и атеротромбоз. Тверь: Триада; 2008.
- Оганов Р. Г., Перова Н. В. Диетотерапия атерогенных дислипопротеидемий. Кардиология 1990; 5: 115-123.
- Leaf A. Dietary prevention of coronary heart disease. The Lyon diet heart study. Circulation 1999; 99: 733-735.
- Grundy S. M. Dietary therapy for different forms of hyperlipoproteinemia. Circulation 1987; 76 (3): 523-528.
- Hunt S. C., Hasstedt S. J., Kuida H. et al. Genetic heritability and common environmental components of resting and stressed blood pressures, lipids and body mass index in Utah pedigrees and twins. Am. J. Epidemiol. 1989; 129: 625-638.
Supplementary files
